The most compelling proof of TACE activity's involvement in MASH‐HCC, mediated by AATF, lies in the observation that Marimastat, a TACE inhibitor, reduces JNK, ERK1/2, and AKT activation in AATF control cells. Here, MAPK3 is linked to hepatocellular carcinoma.